Saved in:
Bibliographic Details
Main Authors: Adam P. Yan, Yuqing Feng, Dima El Hassanieh, Allison Starr, Martin Yi, Tal Schechter‐Finkelstein, Jennifer Drynan, Lillian Sung, Sumit Gupta
Format: Artículo Open Access
Published: Wiley 2025
Subjects:
Online Access:https://onlinelibrary.wiley.com/doi/10.1002/pbc.32032
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867007400184119296
author Adam P. Yan
Yuqing Feng
Dima El Hassanieh
Allison Starr
Martin Yi
Tal Schechter‐Finkelstein
Jennifer Drynan
Lillian Sung
Sumit Gupta
author_facet Adam P. Yan
Yuqing Feng
Dima El Hassanieh
Allison Starr
Martin Yi
Tal Schechter‐Finkelstein
Jennifer Drynan
Lillian Sung
Sumit Gupta
Adam P. Yan
Yuqing Feng
Dima El Hassanieh
Allison Starr
Martin Yi
Tal Schechter‐Finkelstein
Jennifer Drynan
Lillian Sung
Sumit Gupta
collection Wiley Open Access
contents Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience Adam P. Yan Yuqing Feng Dima El Hassanieh Allison Starr Martin Yi Tal Schechter‐Finkelstein Jennifer Drynan Lillian Sung Sumit Gupta Pediatric Blood & Cancer ABSTRACT Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long‐acting monoclonal antibody approved in 2023, offers single‐dose seasonal protection. We conducted a single‐center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024–2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non‐recipients, including one RSV‐related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations. 10.1002/pbc.32032 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/pbc.32032
format Artículo Open Access
id wiley_oa_10_1002_pbc_32032
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience
Adam P. Yan
Yuqing Feng
Dima El Hassanieh
Allison Starr
Martin Yi
Tal Schechter‐Finkelstein
Jennifer Drynan
Lillian Sung
Sumit Gupta
Pediatric Blood & Cancer
Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience Adam P. Yan Yuqing Feng Dima El Hassanieh Allison Starr Martin Yi Tal Schechter‐Finkelstein Jennifer Drynan Lillian Sung Sumit Gupta Pediatric Blood & Cancer ABSTRACT Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long‐acting monoclonal antibody approved in 2023, offers single‐dose seasonal protection. We conducted a single‐center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024–2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non‐recipients, including one RSV‐related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations. 10.1002/pbc.32032 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience
topic Pediatric Blood & Cancer
url https://onlinelibrary.wiley.com/doi/10.1002/pbc.32032